ObjectiveTo investigate the short-term effectiveness of INBONETM Ⅱ total ankle prosthesis arthroplasty in the treatment of moderate to severe varus-type ankle arthritis. MethodsThe clinical and radiographic data of patients with moderate to severe varus-type ankle arthritis, who were admitted between May 2017 and November 2021 and treated with total ankle arthroplasty (TAA) using INBONETM Ⅱ prosthesis, was retrospectively analyzed. A total of 58 patients (58 ankles) met the selection criteria and were included in the study. Among them, there were 24 males and 34 females, with an average age of 62.6 years (range, 41-85 years). According to the preoperative tibiotalar angle (TTA), the patients were divided into a moderate varus group (group A, TTA 5°-15°, n=34) and a severe varus group (group B, TTA>15°, n=24). There was no significant difference in gender, side, etiology, preoperative American Orthopaedic Foot and Ankle Society (AOFAS) score, ankle dorsiflexion, plantarflexion, and total range of motion, and tibial lateral surface angle (TLS) between the two groups (P>0.05). Yet the patients in group A were younger than group B, the degrees of oesteoarthritis (Takakura stage) and ankle pain [visual analogue scale (VAS) score] were milder, and the TTA, talar tilt angle (TT), hindfoot alignment angle (HAA) were smaller while the tibial articular surface angle (TAS) was larger, showing significant differences (P<0.05). The pre- and post-operative VAS score, AOFAS score, the occurrence of early and late complications, the radiographic parameters of the ankle (TTA, TAS, TT, HAA, TLS), ankle dorsiflexion, plantarflexion, and total range of motion were recorded and compared. ResultsAll patients were followed up 19-72 months, with an average of 38.9 months. Compared with the preoperative data, the VAS score of all patients significantly decreased (P<0.05); the AOFAS score, ankle dorsiflexion range of motion, and total range of motion significantly increased (P<0.05); and the TTA, TAS, TT, HAA, and TLS significantly improved at last follow-up (P<0.05); but there was no significant difference in plantarflexion range of motion (P>0.05). Early complications occurred in 13 patients, and only 1 patient underwent revision surgery due to a larger size of the talar component. At last follow-up, there was no significant difference in the difference of clinical parameters before and after operation between the two groups (P>0.05); there was a significant difference in the difference of other radiographic parameters (P<0.05) except TLS. No significant difference in the incidence of complications between the two groups was found (P>0.05). ConclusionTAA using the INBONETM Ⅱtotal ankle prosthesis is an effective treatment for moderate or severe varus-type ankle arthritis, and good clinical and radiographic results can be obtained. Correcting bony deformities and balancing soft tissue are the keys to successful surgery.
Objective To evaluate the early effectiveness of total talar replacement (TTR) with personalized three-dimensional (3D)-printed titanium talus prostheses in the treatment of steroid-induced talar avascular necrosis (TAN). Methods The clinical data of 11 patients with steroid-induced TAN who met the selection criteria between June 2022 and June 2024 were retrospectively analyzed. There were 8 males and 3 females with an average age of 51 years ranging from 26 to 67 years. The duration of hormone use ranged from 12 to 36 months, with an average of 19.6 months. The TTR treatment was performed with the personalized 3D-printed titanium alloy talus prosthesis. Radiographic evaluation was performed preoperatively and at last follow-up to assess prosthesis-related conditions, including loosening, subsidence, and adjacent joint degeneration. Clinical outcomes were assessed using the visual analogue scale (VAS) score, American Orthopaedic Foot & Ankle Society (AOFAS) ankle-hindfoot score, Ankle Osteoarthritis Scale (AOS), 36-Item Short Form Survey (SF-36) [including physical health score (PCS) and mental health score (MCS)], and ankle range of motion (ROM) to assess functional recovery. Results All surgeries were completed successfully. The operation time was 40-60 minutes (mean, 51 minutes), and intraoperative blood loss was 5-20 mL (mean, 10 mL). All incisions healed by first intention without early complications such as infection, skin necrosis, hematoma, neurovascular injury, or deep vein thrombosis. All 11 patients were followed 15-33 months (mean, 22.8 months). One superficial wound infection occurred at 2 weeks postoperatively and resolved after conservative treatment. No prosthetic joint infection, loosening, subsidence, adjacent joint degeneration, or reoperation was observed. At last follow-up, the VAS score, AOFAS ankle-hindfoot score, AOS score, PCS score, and MCS score improved significantly when compared with preoperative ones (P<0.05), whereas ankle ROM showed no significant difference (P>0.05). Conclusion Personalized 3D-printed titanium talus prostheses effectively relieve pain and improve ankle function and quality of life in patients with steroid-induced TAN, providing a viable joint-preserving treatment option.